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Objectives: Few studies have attempted to quantify the costs of operating room 
(OR) time. The purpose of this study is to quantify the variable cost per OR min-
ute in isolated non-robotic valvular procedures – aortic valve replacement (AVR), 
mitral valve replacement (MVR), and mitral valve repair (MVRepair). MethOds: 
The Premier database, one of the most comprehensive hospital databases, was 
queried from 2007 to 2011 for patients undergoing AVR, MVR, or MVRepair. This 
database contains complete billing, hospital cost, and coding data from > 600 US 
facilities. Patients were identified using the following International Classification 
of Diseases 9th Revision (ICD-9) procedure codes: AVR 35.21, 35.22; MVR 35.23, 
35.24; and MVRepair 35.12. Patients having coronary artery bypass grafting were 
excluded. The surgical approaches, right thoracotomy (RT) and any sternal inci-
sion, were identified for each patient with expert clinical assistance. Patients 
with right thoracotomy were then propensity score matched to patients with 
any sternal incision, adjusting for patient differences. Premier classified vari-
able costs of the OR into three categories; staff for the surgery room, anesthe-
sia, and recovery room. Outliers were identified based on the cost per minute 
of the procedure. The top and bottom five percent were removed. All costs were 
adjusted to 2012 dollars using the Medical Care Component of the Consumer Price 
Index. Results: There were 2,657 valvular procedures - 1,604 AVR, 434 MVR, and 
619 MVRepair - that met the inclusion criteria. The average cost per OR minute 
was $28.5 (95% CI $28.1 - $28.9) for all procedures, and $27.8 (95% CI $27.3 – $28.3), 
$31.7 (95% CI $29.5 - $31.9), $28.7 (95% CI $27.9 - $29.5) for AVR, MVR, and MVRepair, 
respectively. cOnclusiOns: Quantifying the variable cost of an OR minute from 
a multi-institution database provides researchers with an important component 
to use in economic evaluations for valvular procedures.
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Objectives: The purpose of this study was to find the trends in total medical 
expenditure and utilization patterns of medical resource for heart failure inpatients 
between years of 2009 and 2011. MethOds: Heart failure patient was defined as 
the one with I50, which is the primary diagnosis ICD-10 code. Patients were iden-
tified from the Korea National Health Insurance Claim’s Sample data in Health 
Insurance Review & Assessment Service (HIRA_NIS data) of 2009 (Serial Number: 
HIRA_NPS_2009-0071) and 2011 (Serial Number: HIRA_NIS_2011-0067). The HIRA_NIS 
data contain 13% of overall inpatient and 1% of ambulatory patient data including 
medical costs and resource utilizations of the patients in Korea (about 1.1 million 
persons per year). The estimated number of total researched patients were 7,410 in 
2009, comprised of 2,571 inpatients and 6,010 outpatients. In 2011, the estimated 
number of patients were 8,557; 2,803 inpatients and 7,189 outpatients. Results: 
The average medical expenditure per inpatient with heart failure had increased to 
14.9% between two years. For all types of hospitals studied, university hospital, gen-
eral hospital, and secondary hospital, the medical cost per inpatient had increased. 
The length of hospitalization had increased to 8.4% in 2011 compared with 2009. In 
both years, essential hypertension and arterial fibrillation & flutter were the most 
prevalent secondary diseases for heart failure inpatients, followed by non-insulin-
dependent diabetes mellitus in 2009 and angina pectoris in 2011. cOnclusiOns: 
Heart failure was a serious disease in terms of the medical expenditure for treat-
ment and the length of hospitalization in both years. The medical expenditure was 
increasing with time. Considering this trend, it can be expected that the economic 
burden for patients, hospitals, and the health care system will continuously be 
increased.
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Objectives: High cholesterol is one of the major risk factors for coronary heart 
disease. The objectives of this study were to examine the prevalence of antihy-
perlipidemic agents use, and provide estimates of the associated outpatient pre-
scription drug utilization and expenditure. MethOds: A cross-sectional study was 
conducted using data from the Medical Expenditure Panel Survey (MEPS) between 
2002 and 2010. Subjects were derived from U.S. civilian and non-institutionalized 
population diagnosed with hyperlipidemia. A series of descriptive analyses were 
performed to estimate the weighted prevalence, utilization, and expenditures for 
the hyperlipidemic patients who received any FDA-approved lipid lowering agent. 
SAS 9.3 statistical software was used for all analyses including sample weights and 
standard error adjustments. Results: The study findings indicated the patients 
diagnosed with hyperlipidemia increased from 17 million to 41 million between 
2002 and 2010. Among these, 94.1% in 2002 vs. 87.8% in 2010 of the patients received 
antilipidemic drugs. However, the utilization of total lipid lowering agents increased 
from 96 million in 2002; to 149 million in 2005; then to 231 million in 2010. The 
drug expenditures showed a significant increase by $12 billion rising from $11.7 
billion in 2002 to $22.8 billion in 2010. cOnclusiOns: Despite the prevalence of a 
noted increase of treatment, utilization and expenditures for those diagnosed with 
hyperlipidemia, there exists a large population of people who remain untreated. 
The study results indicate that further research is needed to improve treatment of 
hyperlipidemia as well as assessing the impact on costs and health care outcomes 
from untreated patients over time.
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Objectives: The purpose of this study was to find the total medical expenditure 
and utilization of trends in medical resource for patients hospitalized and diag-
nosed with heart failure. MethOds: : Heart failure patients were identified from 
the Korean HIRA_NIS Data (National Health Insurance Claims’ Sample data) of 
2011, provided by Health Insurance Review & Assessment Service (HIRA) in South 
Korea. Heart failure inpatient was defined as the one whose primary diagnosis 
ICD-10 code is I50. The analysis of relations between total medical expenditure 
and possible variables are processed through regression analysis. Results: The 
average medical cost per inpatient with heart failure was KRW 3,167,969 (USD 
2,970.16). The medical cost per inpatient showed KRW 3,627,711 (USD 3,401.19) 
KRW 2,500,556 (USD 2,344.42) KRW 1,668,074 (USD 1,563.92) in the university hos-
pitals, general hospitals, and secondary hospitals, respectively. The number of visit 
to hospital for each patient was 1.7 times per year. The average hospital stay for 
inpatient was 24.6 days. The essential hypertension, arterial fibrillation and flutter, 
and angina pectoris were ranked to be the most prevalent secondary disease for 
heart failure in-patients. According to the result of multivariate regression analy-
sis, with observation of 8,557 heart failure inpatients, factors including the age of 
40 and over, male, visit days and renal impairment showed a significant increase 
in total medical expenditure. Especially, renal impairment was the largest impact 
on the increase in treatment cost of heart failure (coefficient= 2,831,614 SD 123,951, 
p< 0.001). cOnclusiOns: Although extra billing cost could not be identified with 
NHI claims data, this analysis suggests that heart failure is a considerable disease 
with great medical expenditure. In consideration of total medical expenditure, it 
can be expected that patients, hospitals, and national health care department are 
currently in severe economic burden.
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Objectives: Advanced heart failure (HF) is a leading cause of death in developed 
countries. One to two percent of the French population is affected by this disease. 
It also causes a substantial economic burden on society and cost 1.6 billion euros 
per year in France. Usually, cardiac transplantation is the most effective treatment. 
However, because of a limited donor organ supply, innovative technics as left ven-
tricular assist devices (LVAD) were developed for over 10 years. This study aims to 
assess the medical and economic consequences of LVAD in adults with advanced HF 
in France during one year after LVAD implantation. MethOds: The primary medi-
cal outcome was the discharge to the patient’s home. Secondary medical outcomes 
were defined as final situation of patient, survival, dependence and quality of life 
(QOL) assessed with the SF-36 and the Minnesota QOL questionnaires. This prospec-
tive economic analysis adopted the health care payer’s perspective and took into 
account direct medical and non-medical costs. Results: Among the 55 patients 
included, 37 were discharged at home during an average of 140 days. At one year, 
23 patients were still on device and spent 238 days at home, 15 were transplanted 
and spent 132 days at home and 17 were died and spent 13 days at home. The mean 
total cost per implanted patient was 164,154±37,104€ . Costs drivers were the device 
(58%) and initial hospitalization (30%). The cost of at home care was 6,084±6,738€ 
accounting for only 4% of total cost. According to the health care payer’s perspective, 
one day spent at home costs 44€ . Survival, QOL and dependence analyses are being 
processed. cOnclusiOns: Continuous- flows LVAD represent a costly strategy in 
the HF treatment but allow the patient to be discharged at home instead of awaiting 
heart transplantation at hospital.
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Objectives: To identify the total in-hospital cost associated with the index hos-
pitalization for the implantation of a left ventricular assistance device (LVAD) in 
a Quebec, Canada setting. MethOds: A retrospective patient chart review was 
conducted in all 3 hospital centers with an active LVAD program to identify all 
patients who underwent LVAD implantation between January 1st 2010 and December 
31st2013. The costing evaluation had 4 distinct components: 1) LVAD acquisition cost; 
2) implantation procedure cost; 3) hospital stay cost; and 4) inpatient drug costs. 
The average cost per patient was calculated. All costs were actualized to 2013 $CDN 
values. Results: A total 65 LVAD-implanted patients were identified between 2010 
and 2013. The majority of these patients were male (n= 49 [75.4%]) and the average 
was 52.2 years old (SD 14.2). Patient-specific costing was completed for 17 of these 
patients. Average index hospitalization stay was 64 days (range 11-140). Average 
per patient cost was $157,073 (range $115,911-222,933). cOnclusiOns: This is the 
first province-wide evaluation of the cost of the index hospitalisation for LVAD 
implantation. These results should inform the decision-making process related to 
future resource allocation for the province’s LVAD program.
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Objectives: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia world-
wide, affecting about 5% of the population over 60 years old. This condition is asso-
ciated with an increased risk of arterial thromboembolism and stroke particularly 
ischemic stroke. Anticoagulant therapy can substantially reduce these complica-
tions. The aim of this analysis is to estimate the non pharmacological costs and 
consequences of the use of apixaban compared with warfarin in the treatment of 
patients with non-valvular atrial fibrillation (NVAF) in Colombia. MethOds: An 
excel model was adapted to simulate the cost and outcomes based on a hypothetic 
cohort of 1,000,000 patients annually. The comparators were: apixaban (5 mg BID) 
with warfarin (INR 2.0 to 3.0). The prevalence of AF data was taken from a local study 
.The effectiveness and safety data were taken from ARISTOTLE study (n= 18,201). 
The analysis used the third payer perspective including only direct medical costs. 
The costs of medical procedures were taken from the ISS tariffs and expressed in 
2013 $ US (1 $ US= 1.934 COP). The results were measured in terms of number of 
events of stroke/systemic embolism, major bleedings and deaths presented annu-
ally. Results: The results were as follows: events of stroke/systemic embolism 
apixaban 73 and warfarina 93; major bleedings apixaban 123 and warfarina 179; 
and deaths apixaban 203 and warfarina 228. The Model results indicate that apixa-
ban compared to enoxaparin would prevent per year: 20 stroke/systemic embolism 
events, 56 major bleedings and 25 deaths. Apixaban compared with warfarin would 
save annually on average $ US 184,227 for the cohort of simulated patients, distrib-
uted as follows: $ US 85,938 (47 %) in care of stroke/systemic embolism and $ US 
98,262 (53 %) in care of major bleedings. cOnclusiOns: In this analysis, apixaban 
demonstrates better expected health outcomes with lower expected associated 
costs, in the Colombian health system.
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Objectives: Thrombolysis has not been fully implemented into clinical practice in 
the developing world primarily due to economic restraints. The study assessed the 
cost-effectiveness (CE) and estimated annual savings of thrombolysis with recom-
binant tissue plasminogen activator (rt-PA, alteplase) within 4.5 hours after acute 
ischemic stroke (AIS) versus standard care from the Mexican Institute of Social 
Security (IMSS) perspective. Standard care (SC) was defined as inpatient treatment of 
the AIS without utilization of thrombolytic agents. MethOds: A decision-analytic 
model was developed. Efficacy, direct costs and resources were obtained from IMSS 
available data and published studies. Effectiveness outcomes included the percent-
age of patients who responded favorably to treatment (no disability and able to 
carry out all usual activities) between the time of diagnosis + 1 year (time horizon). 
Additionally analyses evaluated cost savings in patients with AIS (> 80 years old) 
who responded favorably to the treatment. Discount rates were not applied to the 
model. A sensitivity analysis was conducted to evaluate the impact of the uncer-
tainty variables. Results: The estimated total cost per patient was $23,53.20 for 
SC and $23,663.93 for rt-PA. The percentage of patients who responded favorably 
to treatment was 16% in the rt-PA and 12% in SC. The CER were USD $193,241.02 
for SC and USD$146,924.34 for rt-PA. This equated to a cost-savings of $46,316.67/
percentage of patients recovered with no symptoms/disabilities. The projected sav-
ings over a five-year period (2013-2017) in the IMSS ranged from $9,626,458 and 
$22,015,454. cOnclusiOns: The results from the analyses indicated that rt-PA pro-
vided a highly cost-effective and saving alternative compared with SC. In medical 
settings where thrombolysis is not yet a common practice, rt-PA is a cost effective 
treatment to improve functional outcome in patients treated promptly after acute 
ischemic stroke.
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Objectives: To analyse the incremental cost-effectiveness ratio (ICER) between 
combination angiotensin II receptor antagonists + thiazides. Specifically, compar-
ing azilsartan + clortalidona vs. current available treatments: valsartan + hydro-
chlorothiazide, telmisartan + hydrochlorothiazide, losartan + hydrochlorothiazide 
and irbesartan + hydrochlorothiazide. MethOds: Cost-effectiveness analysis was 
conducted using a Markov model with a 35-year temporal horizon for patients 
over the age of 45 and diagnosed with systemic arterial hypertension. The model 
adopts the Mexican public health institutions’ perspective. Four health states were 
incorporated: healthy, hypertensive with non-fatal acute myocardial infarction 
(AMI), hypertensive with non-fatal stroke and death. Transition probabilities were 
calculated based on the national risk of stroke or AMI, and the probability of hav-
ing a vascular complication depending on blood pressure levels (in mmHg). Costs 
and effectiveness data were taken from public health institutions, producer phar-
maceutical companies or extracted from published literature. Final outcome was 
measured in ICER per life year gained (LYG). Cost-effectiveness was determined 
according to the 1GDP/capita threshold established by the National Health Council 
in Mexico. Results: Azilsartan + chlortalidone was found to be dominant com-
pared to all other treatments with a total cost of USD$2,873.57 over 35 years, and 
an effectiveness of 12.23 LYG. The next most cost-effective comparator, losartan + 
hydrochlorothiazide, presented an ICER of USD$349.21; however due to a difference 
in efficacy of -0.68 LYG, azilsartan + chlortalidone remained dominant even with a 
10% increase in price. cOnclusiOns: Azilsartan + chlortalidone was found to be 
dominant in comparison with all other included treatments. Azilsartan is therefore 
a very cost-effective intervention for the Mexican population over 45 with systemic 
arterial hypertension.
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Objectives: To compare costs and effectiveness of dabigatran versus factor 
Xa inhibitors (apixaban and rivaroxaban) in patients with non-valvular atrial 
fibrillation (NVAF) from a private and public health care system perspective in 
Brazil. MethOds: The cost-effectiveness analysis was based on Markov modeling, 
and estimated the costs and clinical outcomes, in a lifetime horizon, associated to 
dabigatran, apixaban and rivaroxaban in patients with NVAF. Epidemiological and 
efficacy data derived from international literature and a modified Delphi panel 
with Brazilian experts (local clinical practice pattern on the management of NVAF 
patients). The model estimated the number of events (ischaemic strokes, systemic 
embolisms, transient ischaemic attacks) associated with the respective treatments. 
To each clinical event costs, disabilities and/or reduction in quality of life, and risk 
of death were assigned. Only direct medical costs were considered and obtained 
from Brazilian official databases. Costs and benefits were discounted at 5% yearly, 
according to Brazilian Health Technologies Assessment guidelines. Sensitivity analy-
sis was designed to assess uncertainty. Results: Considering 100 patients, base 
case analysis showed that dabigatran was associated with additional 4.6 life years 
(LY), additional 4.3 QALYs, and demonstrated a lower incidence of events (1,4 events 
avoided) versus apixaban. Compared to rivaroxaban, dabigatran was also associ-
ated with additional 17.8 life years (LY), additional 19.3 QALYs, and demonstrated a 
lower incidence of events (2.8 events avoided). Under both perspectives and versus 
both comparators, dabigatran was associated with lower costs. Sensitivity analyses 
confirmed the favorable results of the base case. cOnclusiOns: Findings suggest 
that dabigatran is a dominant option for stroke prevention when used instead of 
direct factor Xa inhibitors (apixaban or rivaroxaban) in NVAF patients from the 
Brazilian public and private health care system perspective.
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Objectives: The purpose of this study was to assess the predictive validity of an 
apixaban cost-effectiveness model by comparing key event rates from the model 
to those seen in the ARISTOTLE trial where apixaban was compared with vitamin K 
antagonist (VKA) in patients with non-valvular atrial fibrillation (NVAF). MethOds: 
A Markov model was developed to assess the cost effectiveness of apixaban versus 
comparators including VKA. The model was set to the settings of the ARISTOTLE 
and the key event rates were compared by setting time horizon same as ARISTOTLE. 
Predictive validity of the model was checked by comparing key outcomes to the 
source data. Results: Overall, the model closely predicted event-based hazard ratio 
(HR) for warfarin versus apixaban for various end-points including ischemic and 
unspecified stroke (HR: 1.09 vs 1.08 for trial vs. model). Similar results were observed 
for intracranial hemorrhages (HR: 2.38 vs. 2.25), other major bleeds (HR: 1.27 vs. 1.24) 
and myocardial infarction (HR: 1.14 vs. 1.13). Importantly, death was accurately pre-
dicted by this model with HR of 1.13 vs. 1.12 seen in the trial. Slight variations in the 
HR may be attributable to the sequential structure of the model where event rates 
associated with aspirin therapy after warfarin discontinuation were derived from 
AVERROES patients on aspirin who were previously treated with warfarin (@42%). 
Other major bleeds and clinically relevant non-major bleeds rates were slightly 
different, as these events were modeled as transient states to mimic real life treat-
ment patterns. cOnclusiOns: The model appears to predict event rates seen in 
ARISTOTLE trial, thus demonstrating the model’s ability to accurately replicate the 
trial results within the trial period. This study demonstrates the applicability of this 
model to estimate cost-effectiveness of new interventions in similar populations.
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CosT effeCTiVeness of drug eluTing balloon Versus PerCuTaneous 
Transluminal balloon angioPlasTy, bare meTal sTenT and drug 
eluTing sTenT in The TreaTmenT of PeriPheral arTerial disease in 
lower limbs Colombia
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Objectives: Cost-Effectiveness analysis of Drug Eluting Balloon (DEB) vs. 
Percutaneous Transluminal Balloon Angioplasty (PTA), Bare Metal Stent (BMS) and 
